Plan for ¥39 million net loss attributable to owners of parent for the current consolidated fiscal year
First written in FY2019-Q1. 2 of 4 entries say "Worsened", first in FY2019. Latest entry: FY2021.
Immuno-Biological Laboratories moved to the "Worse" side of this theme in 2019.
0 other companies' latest entry also says "Dropped".
- FY2021DroppedAnnual reportThe filing does not contain any reference to the plan for a net loss attributable to owners of the parent of ¥39.000 million for FY2020, as the plan period has expired.
- FY2020WorsenedAnnual report
「For the fiscal year, the group's medium-term plan, which began in that fiscal year, projected a net loss attributable to owners of the parent of ¥565.000 million.」
Against the medium-term plan's projected net loss attributable to owners of the parent of ¥565.000 million, the actual loss was ¥668.125 million, exceeding the planned loss. - FY2019WorsenedAnnual report
「The net loss attributable to owners of the parent was ¥167.319 million, primarily because the company recognized an impairment loss on land it held, compared with a net loss attributable to owners of the parent of ¥52.637 million in the same period of the previous year.」
The net loss attributable to owners of the parent for the fiscal year was ¥167.319 million, substantially exceeding the ¥39.000 million figure set out in the plan. - FY2019-Q1First statedAnnual report
「The group's plan for the fiscal year calls for a net loss attributable to owners of the parent of ¥39.000 million. Taking into account investments in property, plant and equipment, changes in inventories and other items, and tax payments, the company expects the asset base to decline slightly from its current level.」
The company has disclosed for the first time a numerical plan for a net loss attributable to owners of the parent of ¥39.000 million for the fiscal year.